MAGL Inhibitor Compound 23 |
Catalog No.GC41185 |
MAGL Inhibitor Compound 23 is a potent, selective, reversible and competitive inhibitor of MAGL, with an IC50 of 80 nM. MAGL Inhibitor Compound 23 exhibits anti-proliferative effects against human breast, colorectal, and ovarian cancer cells. MAGL Inhibitor Compound 23 blocks MAGL in cell-based as well as in vivo assays.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2324160-91-8
Sample solution is provided at 25 µL, 10mM.
MAGL inhibitor compound 23 is an inhibitor of monoacylglycerol lipase (MAGL; IC50 = 80 nM). It is selective for MAGL over cannabinoid receptor 1 (CB1), CB2, fatty acid amide hydrolase (FAAH), α/β-hydrolase domain-containing protein 6 (ABHD6), and ABHD12 (IC50s = >10 μM). MAGL inhibitor compound 23 inhibits the growth of HCT116, MDA-MB-231, Caov-3, OVCAR-3, and SKOV3 cells (IC50s = 21, 7.9, 25, 57, and 15 μM, respectively) but not MRC5 cells (IC50 = >100 μM). It increases the levels of 2-arachidonoyl glycerol in mouse brain and plasma when administered at a dose of 50 mg/kg.
Average Rating: 5
(Based on Reviews and 35 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *